FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897072723> ?p ?o ?g. }

• W2897072723 endingPage "e0204973" @default.
• W2897072723 startingPage "e0204973" @default.
• W2897072723 abstract "Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. Onapristone is active in multiple preclinical models and two prior studies demonstrated promising activity in patients with breast cancer. We conducted a study of extended release (ER) Onapristone to determine a recommended dose and explore the role of transcriptionally-activated PR (APR), detected as an aggregated subnuclear distribution pattern, as a predictive biomarker.An open-label, multicenter, randomized, parallel-group, phase 1 study (target n = 60; NCT02052128) included female patients ≥18 years with PRpos tumors. APR analysis was performed on archival tumor tissue. Patients were randomized to five cohorts of extended release (ER) onapristone tablets 10, 20, 30, 40 or 50 mg BID, or immediate release 100 mg QD until progressive disease or intolerability. Primary endpoint was to identify the recommended phase 2 dose. Secondary endpoints included safety, clinical benefit and pharmacokinetics.The phase 1 dose escalation component of the study is complete (n = 52). Tumor diagnosis included: endometrial carcinoma 12; breast cancer 20; ovarian cancer 13; other 7. Median age was 64 (36-84). No dose limiting toxicity was observed with reported liver function test elevation related only to liver metastases. The RP2D was 50 mg ER BID. Median therapy duration was 8 weeks (range 2-44), and 9 patients had clinical benefit ≥24 weeks, including 2 patients with APRpos endometrial carcinoma.Clinical benefit with excellent tolerance was seen in heavily pretreated patients with endometrial, ovarian and breast cancer. The data support the development of Onapristone in endometrial endometrioid cancer. Onapristone should also be evaluated in ovarian and breast cancers along with APR immunohistochemistry validation." @default.
• W2897072723 created "2018-10-26" @default.
• W2897072723 creator A5010518407 @default.
• W2897072723 creator A5020762807 @default.
• W2897072723 creator A5024118579 @default.
• W2897072723 creator A5032111284 @default.
• W2897072723 creator A5034058277 @default.
• W2897072723 creator A5034376000 @default.
• W2897072723 creator A5034474315 @default.
• W2897072723 creator A5042956778 @default.
• W2897072723 creator A5043109982 @default.
• W2897072723 creator A5044020087 @default.
• W2897072723 creator A5056565799 @default.
• W2897072723 creator A5057002841 @default.
• W2897072723 creator A5060949051 @default.
• W2897072723 creator A5069069870 @default.
• W2897072723 creator A5071553983 @default.
• W2897072723 creator A5072055304 @default.
• W2897072723 creator A5079169911 @default.
• W2897072723 creator A5083914679 @default.
• W2897072723 creator A5090767491 @default.
• W2897072723 creator A5091655083 @default.
• W2897072723 date "2018-10-10" @default.
• W2897072723 modified "2023-10-11" @default.
• W2897072723 title "Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers" @default.
• W2897072723 cites W101268677 @default.
• W2897072723 cites W1829077072 @default.
• W2897072723 cites W1933506009 @default.
• W2897072723 cites W1976158428 @default.
• W2897072723 cites W1983361249 @default.
• W2897072723 cites W2002357201 @default.
• W2897072723 cites W2012904520 @default.
• W2897072723 cites W2023298070 @default.
• W2897072723 cites W2023946729 @default.
• W2897072723 cites W2048957217 @default.
• W2897072723 cites W2056834448 @default.
• W2897072723 cites W2057895871 @default.
• W2897072723 cites W2062773135 @default.
• W2897072723 cites W2072036336 @default.
• W2897072723 cites W2077470442 @default.
• W2897072723 cites W2103192143 @default.
• W2897072723 cites W2103512826 @default.
• W2897072723 cites W2114500987 @default.
• W2897072723 cites W2116591759 @default.
• W2897072723 cites W2117445233 @default.
• W2897072723 cites W2132720740 @default.
• W2897072723 cites W2135024929 @default.
• W2897072723 cites W2139425717 @default.
• W2897072723 cites W2142973385 @default.
• W2897072723 cites W2153954237 @default.
• W2897072723 cites W2155916082 @default.
• W2897072723 cites W2158907708 @default.
• W2897072723 cites W2166099282 @default.
• W2897072723 cites W2244282744 @default.
• W2897072723 cites W2324878183 @default.
• W2897072723 cites W2339869474 @default.
• W2897072723 cites W2531506996 @default.
• W2897072723 cites W2564062827 @default.
• W2897072723 cites W2595856813 @default.
• W2897072723 cites W79525222 @default.
• W2897072723 doi "https://doi.org/10.1371/journal.pone.0204973" @default.
• W2897072723 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6179222" @default.
• W2897072723 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30304013" @default.
• W2897072723 hasPublicationYear "2018" @default.
• W2897072723 type Work @default.
• W2897072723 sameAs 2897072723 @default.
• W2897072723 citedByCount "18" @default.
• W2897072723 countsByYear W28970727232019 @default.
• W2897072723 countsByYear W28970727232020 @default.
• W2897072723 countsByYear W28970727232021 @default.
• W2897072723 countsByYear W28970727232022 @default.
• W2897072723 countsByYear W28970727232023 @default.
• W2897072723 crossrefType "journal-article" @default.
• W2897072723 hasAuthorship W2897072723A5010518407 @default.
• W2897072723 hasAuthorship W2897072723A5020762807 @default.
• W2897072723 hasAuthorship W2897072723A5024118579 @default.
• W2897072723 hasAuthorship W2897072723A5032111284 @default.
• W2897072723 hasAuthorship W2897072723A5034058277 @default.
• W2897072723 hasAuthorship W2897072723A5034376000 @default.
• W2897072723 hasAuthorship W2897072723A5034474315 @default.
• W2897072723 hasAuthorship W2897072723A5042956778 @default.
• W2897072723 hasAuthorship W2897072723A5043109982 @default.
• W2897072723 hasAuthorship W2897072723A5044020087 @default.
• W2897072723 hasAuthorship W2897072723A5056565799 @default.
• W2897072723 hasAuthorship W2897072723A5057002841 @default.
• W2897072723 hasAuthorship W2897072723A5060949051 @default.
• W2897072723 hasAuthorship W2897072723A5069069870 @default.
• W2897072723 hasAuthorship W2897072723A5071553983 @default.
• W2897072723 hasAuthorship W2897072723A5072055304 @default.
• W2897072723 hasAuthorship W2897072723A5079169911 @default.
• W2897072723 hasAuthorship W2897072723A5083914679 @default.
• W2897072723 hasAuthorship W2897072723A5090767491 @default.
• W2897072723 hasAuthorship W2897072723A5091655083 @default.
• W2897072723 hasBestOaLocation W28970727231 @default.
• W2897072723 hasConcept C121608353 @default.
• W2897072723 hasConcept C126322002 @default.
• W2897072723 hasConcept C126894567 @default.
• W2897072723 hasConcept C143998085 @default.

• next